AMRX

Handel nachbörslich: 17.92 0.17 +0.96%

Amneal Pharmaceuticals Inc (AMRX)

Überblick Nachrichten Preisverlauf Optionskette Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile

Amneal Pharmaceuticals Inc

Healthcare (1071)

908-947-3120

400 Crossing Boulevard, 3rd Floor, Bridgewater

@amnealpharma

Nächster Verdiensttermin

Neueste SEC-Einreichungen

AMRX's Discussions on Twitter

Compare AMRX vs TAK, HLN, TEVA, ZTS, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
AMRX Amneal Pharmaceuticals Inc	17.75	5.78B	3.05B	181.32M	186.11M	0.373
TAK Takeda Pharmaceutical Co Adr	16.87	55.02B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.85	43.69B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	30.15	36.50B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	74.19	31.59B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	527.07	26.69B	3.17B	1.29B	1.01B	27.09

Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-04-17	Eingeleitet	UBS	Buy
2025-12-09	Eingeleitet	Barclays	Overweight
2025-06-06	Eingeleitet	Goldman	Buy
2025-02-24	Hochstufung	JP Morgan	Neutral → Overweight
2024-09-06	Hochstufung	JP Morgan	Underweight → Neutral
2021-04-07	Fortgesetzt	RBC Capital Mkts	Sector Perform
2021-03-08	Hochstufung	Goldman	Sell → Buy
2020-12-14	Hochstufung	Barclays	Equal Weight → Overweight
2020-12-14	Hochstufung	Guggenheim	Neutral → Buy
2020-07-27	Eingeleitet	Goldman	Sell
2020-05-12	Hochstufung	Guggenheim	Sell → Neutral
2019-12-12	Herabstufung	Raymond James	Outperform → Mkt Perform
2019-11-12	Herabstufung	JP Morgan	Neutral → Underweight
2019-11-07	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2019-07-22	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2019-07-11	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2019-07-08	Hochstufung	Piper Jaffray	Neutral → Overweight
2019-06-11	Eingeleitet	Barclays	Equal Weight
2019-05-21	Hochstufung	Raymond James	Mkt Perform → Strong Buy
2019-03-20	Eingeleitet	SunTrust	Buy
2019-03-08	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2018-12-14	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2018-10-16	Herabstufung	SunTrust	Buy → Hold
2018-08-13	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2018-07-23	Eingeleitet	Morgan Stanley	Overweight
2018-06-22	Eingeleitet	B. Riley FBR, Inc.	Buy

Alle ansehen

Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten

Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)

Amneal Pharmaceuticals Inc (AMRX)

Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile

Compare AMRX vs TAK, HLN, TEVA, ZTS, UTHR

Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades

Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten

Amneal: Kashiv Deal Fuels Biosimilar Growth, But Stock Already Prices In Optimism (AMRX) - Seeking Alpha

Here's why Amneal Pharmaceuticals (AMRX) is a strong growth stock - MSN

Amneal Pharmaceuticals (AMRX) Proxy filing Summary - Quartr

How First-Generic OMNIPAQUE Rivals At Amneal Pharmaceuticals (AMRX) Have Changed Its Investment Story - Sahm

Amneal receives FDA approval for additional iohexol strengths By Investing.com - Investing.com South Africa

Amneal receives FDA approval for additional iohexol strengths - Investing.com

Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations - The Manila Times

Amneal Pharmaceuticals Receives FDA Approval for Additional Iohexol Injection Strengths and Vial Presentations - Quiver Quantitative

Amneal's FDA-approved contrast options give hospitals more vial choices - Stock Titan

Amneal gains FDA approval for four iohexol products - grafa.com

Amneal Pharmaceuticals stock hits 52-week high at 17.86 USD By Investing.com - Investing.com South Africa

Amneal Pharmaceuticals stock hits 52-week high at 17.86 USD - Investing.com

Is Amneal Pharmaceuticals (AMRX) Fairly Valued After Its Sharp Rerating? - Sahm

Amneal Pharmaceuticals (AMRX) Barclays 28th Annual Global Healthcare Conference summary - Quartr

Amneal Pharmaceuticals stock holds steady as generic pipeline supports long term growth - Ad-hoc-news.de

Amneal schedules July 30 call for second-quarter 2026 results - Stock Titan

Amneal to Report Second Quarter 2026 Results on July 30, 2026 - The Manila Times

Amneals Planned Sterile Facility Creates Opportunity For Aseptic Filling Isolator And Automation Suppliers - Pharmaceutical Online

Enterprise value to revenue forward of Amneal Pharmaceuticals, Inc. – NASDAQ:AMRX - TradingView

Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers - Yahoo Finance

Amneal Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Kiely John - Moomoo

Amneal Sues Alembic to Block Copies of Crexont Parkinson’s Drug - Bloomberg Law News

Amneal Pharmaceuticals updates investors on its generics and specialty pipeline. The company focuses - ad-hoc-news.de

$2M from Amneal targets Parkinson's drug costs for patients - Stock Titan

Amneal Pharmaceuticals (AMRX) Gets EU Backing For Hopledo, Is It Fully Priced? - Sahm

Price to sales forward of Amneal Pharmaceuticals, Inc. – NASDAQ:AMRX - TradingView

Amneal Pharmaceuticals : New U.S. Sterile Manufacturing Facility Selected for FDA PreCheck Pilot Program - marketscreener.com

Price to book forward of Amneal Pharmaceuticals, Inc. – NASDAQ:AMRX - TradingView

Price to earnings forward of Amneal Pharmaceuticals, Inc. – NASDAQ:AMRX - TradingView

Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness - Sahm

Lilly, Regeneron selected for US program to review new manufacturing plants faster - Reuters

Amneal to Buy Kashiv for $375M Cash + 28.9M Shares (NASDAQ: AMRX) - Stock Titan

EMA Recommends Approval of Hopledo for Parkinson's Disease - Intellectia AI

Zambon and Amneal Receive Positive CHMP Opinion for Hopledo in Parkinson’s Disease in Europe - Quiver Quantitative

Does Amneal (AMRX) Joining Three Russell 2000 Defensive Indexes Recast Its Risk Profile? - simplywall.st

Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell 2000 Value-Defensive Index - marketscreener.com

Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell 2000 Growth-Defensive Index - marketscreener.com

Amneal Pharmaceuticals, Inc.(NasdaqGS: AMRX) added to Russell 2000 Defensive Index - marketscreener.com

Form DEF 14A Amneal Pharmaceuticals Inc Class A For: 26 June - Investing.com UK

2DT Forecast — Price Target — Prediction for 2027 - TradingView

Amneal Pharmaceuticals, Inc. Class A Actuals & Estimates (NASDAQ:AMRX) - TradingView

AMRX Forecast — Price Target — Prediction for 2027 - TradingView

Amneal Pharmaceuticals (AMRX) Short Interest & Short Float | Updated Jun 2026 - MarketBeat

Amneal Pharmaceuticals advances after securing FDA clearance for cancer treatment (AMRX) - MSN

Amneal Pharmaceuticals stock hits 52-week high at 16.62 USD - Investing.com

Amneal Pharmaceuticals stock hits 52-week high at 16.62 USD By Investing.com - Investing.com South Africa

Rytvela from Amneal Pharmaceuticals Inc.biosimilar for chronic uveitis care - AD HOC NEWS

Amgen Inc. v. Amneal Pharm. LLC United States Court of Appeals of the Federal Circuit, 2020 945 F.3d 1368, 2020 - Sage Journals

Amneal Pharmaceuticals (AMRX) Stock Could Be 6% Below Fair Value After Its Sharp Rally - Sahm

Amneal (AMRX) agrees to buy Kashiv for $375M cash plus equity and milestones - Stock Titan

Amneal Pharmaceuticals Inc (AMRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie AMRX